© 2009 American Public Health Association DOI: 10.2105/AJPH.2008.155234
Rajiv N. Rimal, Jane Brown, Glory Mkandawire, Lisa Folda, and Kirsten Böse are with the Center for Communication Programs, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD. Alisha Creel is with the Uniformed Services University of the Health Sciences, Bethesda, MD. Correspondence: Correspondence should be sent to Rajiv N. Rimal, Department of Health, Behavior & Society, 624 N. Broadway, No. 739, Baltimore, MD 21205 (e-mail: rrimal{at}jhsph.edu). Reprints can be ordered at http://www.ajph.org by clicking the "Reprints/Eprints" link.
Objectives. We sought to determine whether individuals' risk perceptions and efficacy beliefs could be used to meaningfully segment audiences to assist interventions that seek to change HIV-related behaviors. Methods. A household-level survey of individuals (N = 968) was conducted in 4 districts in Malawi. On the basis of responses about perceptions of risk and beliefs about personal efficacy, we used cluster analysis to create 4 groups within the risk perception attitude framework: responsive (high risk, strong efficacy), avoidance (high risk, weak efficacy), proactive (low risk, strong efficacy), and indifference (low risk, weak efficacy). We ran analysis of covariance models (controlling for known predictors) to determine how membership in the risk perception attitude framework groups would affect knowledge about HIV, HIV-testing uptake, and condom use. Results. A significant association was found between membership in 1 or more of the 4 risk perception attitude framework groups and the 3 study variables of interest: knowledge about HIV (F8, 956 = 20.77; P < .001), HIV testing uptake (F8, 952 = 10.91; P < .001), and condom use (F8, 885 = 29.59; P < .001). Conclusions. The risk perception attitude framework can serve as a theoretically sound audience segmentation technique that can be used to determine whether messages should augment perceptions of risk, beliefs about personal efficacy, or both. This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||